Influence of Cyp2c9 and Cyp2c19 Genetic Polymorphisms on Pharmacokinetics and Pharmacodynamics of Gliclazide in Healthy Chinese Han Volunteers

H. Shao,X. M. Ren,N. F. Liu,G. M. Chen,W. L. Li,Z. H. Zhai,D. W. Wang
DOI: https://doi.org/10.1111/j.1365-2710.2009.01134.x
2010-01-01
Journal of Clinical Pharmacy and Therapeutics
Abstract:Background and objective:  CYP2C9 is the major contributor to gliclazide metabolic clearance in vitro, while the pharmacokinetics of gliclazide modified release are affected mainly by CYP2C19 genetic polymorphisms in vivo. This study aims to investigate the influence of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.
What problem does this paper attempt to address?